CoChat
Sign Up
Cited by 27

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Serum biomarkers of drug‐induced liver injury: Current status and future directions

Church, Rachel J., Watkins, Paul B.·2019·Journal of Digestive Diseases
DOI 10.1111/1751-2980.12684
Open this paper in CoChat — free account

Abstract

Drug‐induced liver injury (DILI), which is caused by drugs and herbal or dietary supplements, remains a serious concern for drug developers, regulators, and clinicians; however, serum biomarkers utilized to detect and monitor DILI have not changed in decades and have limitations. Data‐driven mathematical modeling that incorporates the release and clearance kinetics of traditional biomarkers has improved their use in the prediction of liver safety liabilities for new drug candidates. Several newer biomarkers have shown promise in terms of liver specificity, predicting the outcome of DILI events, and providing insight into its underlying mechanisms. For these new biomarkers to be qualified for regulatory acceptance, it will require their assessment in large numbers of patients who are receiving a wide range of compounds and who develop a broad spectrum of liver injuries. The ongoing and evolving international biomarker consortia should play a major role in this effort, which is likely to transform the assessment of liver safety in clinical trials and in the clinic.

Overview

Integrity signals

Registry

Crossref · 10.1111/1751-2980.12684

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • DILI-specific biomarkers have not yet been fully translated into the clinic.

    “Although research into the discovery and qualification of DILI‐specific biomarkers has yielded interesting results, these have not yet been fully translated into the clinic”

    From Methods for causality assessment of idiosyncratic drug‐induced liver injury (2025) · cites this paper as [12]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 72

  1. 10.1111/liv.13535 · DOI
  2. 10.1055/s-2008-1073114 · DOI
  3. 10.1016/j.gastro.2005.05.006 · DOI
  4. 10.1053/j.gastro.2015.03.006 · DOI · Paper page
  5. 10.1002/hep.20800 · DOI · Paper page
  6. 10.1038/ajg.2015.283 · DOI
  7. 10.1093/toxsci/kfw218 · DOI
  8. 10.1055/s-0034-1375954 · DOI
  9. 10.1038/clpt.2011.58 · DOI
  10. 10.1097/FPC.0b013e3283589a76 · DOI
  11. 10.1111/j.1365-2125.2007.03001.x · DOI
  12. 10.1016/j.nmd.2013.09.004 · DOI
  13. 10.1055/s-0029-1240008 · DOI
  14. 10.7326/0003-4819-100-5-646 · DOI
  15. 10.1038/clpt.2012.40 · DOI
  16. Pravastatin Multicenter Study Group II, 1993, Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia, Arch Intern Med., 153, 1321, 10.1001/archinte.1993.00410110029006 · DOI
  17. 10.1186/2050-6511-15-42 · DOI
  18. 10.1378/chest.68.2.181 · DOI
  19. 10.1056/NEJM199803263381314 · DOI
  20. 10.1038/nbt0317-187 · DOI
  21. 10.1053/j.gastro.2014.03.050 · DOI · Paper page
  22. 10.1002/pds.1211 · DOI
  23. 10.1002/hep.29283 · DOI · Paper page
  24. 10.1177/1535370217740853 · DOI
  25. 10.1124/dmd.113.055772 · DOI
  26. 10.1053/j.gastro.2014.03.047 · DOI
  27. 10.3109/00498254.2013.820006 · DOI
  28. 10.1155/2015/635670 · DOI
  29. 10.3109/10408368009108725 · DOI
  30. 10.1111/liv.12834 · DOI
  31. 10.1177/0192623313499976 · DOI
  32. 10.1038/psp.2013.74 · DOI
  33. 10.1002/path.1711170307 · DOI
  34. Chung J, A rapid method to estimate hepatocyte loss due to drug‐induced liver injury [publish online ahead of print October 10, 2018], Clin Pharmacol Ther
  35. 10.1002/cpt.711 · DOI
  36. 10.1093/toxsci/kfx222 · DOI
  37. 10.1002/cpt.619 · DOI
  38. 10.1111/liv.13441 · DOI
  39. 10.1186/s12864-016-2958-x · DOI
  40. 10.1186/s12864-016-2956-z · DOI
  41. 10.1016/S0960-9822(02)00809-6 · DOI · Paper page
  42. 10.1007/s13238-012-2036-3 · DOI
  43. 10.1080/1354750X.2016.1269131 · DOI
  44. 10.1093/toxsci/kfu232 · DOI · Paper page
  45. 10.1111/liv.13312 · DOI
  46. 10.1038/srep15501 · DOI
  47. 10.1073/pnas.1412608111 · DOI
  48. 10.1002/hep.26294 · DOI
  49. 10.1016/S2468-1253(17)30266-2 · DOI · Paper page
  50. 10.1111/bcp.12214 · DOI
  51. 10.1016/0009-8981(88)90356-7 · DOI
  52. Lindena J, 1986, Catalytic enzyme activity concentration in tissues of man, dog, rabbit, guinea pig, rat and mouse. Approach to a quantitative diagnostic enzymology, III. Communication, J Clin Chem Clin Biochem, 24, 35
  53. 10.1172/JCI59755 · DOI
  54. 10.1002/hep.27265 · DOI · Paper page
  55. 10.1093/toxsci/kft009 · DOI
  56. Church RJ, Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: an international collaborative effort [published online ahead of print January 22, 2018], Hepatology
  57. 10.1093/toxsci/kft087 · DOI
  58. Proctor WR, 2016, Development and qualification of assays to detect circulating miR‐122 in rat and human serum to support preclinical and clinical studies, Toxicologist.
  59. 10.1002/hep.29863 · DOI
  60. 10.1053/j.gastro.2016.07.031 · DOI
  61. 10.1053/j.gastro.2017.08.013 · DOI
  62. 10.1038/srep09991 · DOI
  63. 10.1093/toxsci/kfw047 · DOI
  64. 10.1093/toxsci/kfx206 · DOI
  65. 10.1016/j.bbrc.2004.03.057 · DOI
  66. 10.1016/j.cyto.2015.02.021 · DOI
  67. 10.1371/journal.pone.0081974 · DOI
  68. 10.1016/j.jhep.2016.05.003 · DOI · Paper page
  69. 10.1093/toxsci/kfv260 · DOI
  70. 10.1097/MPG.0b013e318264e648 · DOI
  71. 10.1016/j.cellsig.2014.01.003 · DOI
  72. Leonard TB, 1984, Serum gamma glutamyl transferase as a specific indicator of bile duct lesions in the rat liver, Am J Pathol., 116, 262

Cited by

Sorted by citations

Metadata

Authors
Church, R. J., & Watkins, P. B.
Affiliations
Institute for Drug Safety Sciences University of North Carolina at Chapel Hill Research Triangle Park North Carolina USA
Venue
Journal of Digestive Diseases
Publisher
Wiley
Published
2018-12-05
Volume
20
Issue
1
Pages
2-10
ISSN
  • 1751-2972
  • 1751-2980
DOI
10.1111/1751-2980.12684
Cited by
27
References
6
Language
en
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review